Article Sidebar
Published:
Oct 8, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of oral roxadustat combined with L-carnitine for dialysis-induced anemia in patients with chronic renal failure
Abstract
Purpose: To investigate the efficacy of oral roxadustat plus L-carnitine for dialysis-induced anemia in patients with chronic renal failure (CRF).
Methods: This was a retrospective analysis of 46 patients conducted on 100 CRF cases with dialysisinduced anemia treated at Xinjiang Armed Police Crops Hospital from March 2020 to March 2023. The participants were randomly distributed into study (n = 54) and control groups (n = 46). The control group received oral roxadustat (100 mg for patients weighing 45 - 60 kg, and 120 mg for patients ≥ 60 kg, thrice per week), while the study group was administered roxadustat in combination with L-carnitine (2 g injected using the dialysis machine before the end of each session). Anemia indices, and iron metabolism indices in the two groups were assessed before treatment and 3 months after treatment. Adverse effects were compared between groups.
Results: The study group showed significantly higher red blood cell count, haemoglobin level as well as haematocrit after treatment compared to control group (p > 0.05). Also, total iron binding capacity, and serum iron and ferritin levels were significantly higher in the study group than in the control group (p < 0.05).
Conclusion: Roxadustat combined with L-carnitine significantly reduces anemia and improves iron metabolism without increasing adverse reactions. However, there is a need for additional studies to assess the therapeutic potential of this combined regimen.
